Home Services Hospitals Doctors Treatment & Verification Compare Pre-Departure Patient Stories Resources About FAQ Consult Now
EN ES PT AR
Oncology & Cancer Care

Liver Cancer (HCC)

China accounts for ~50% of global HCC cases. Top centers offer hepatectomy, TACE, ablation, transplant, and donafenib (NMPA-approved).

2
Treatment Options
4
Recommended Centers
$3,000
Starting From
7-21 days
Typical Wait

Treatment Plans for Liver Cancer (HCC)

Compare evidence-based options at top Chinese hospitals — transparent pricing, typical wait, and recovery time.

Transarterial Chemoembolization (TACE)

Image-guided injection of chemotherapy and embolic agents directly into liver tumor blood supply.

Wait Time
5-7 days
Hospital Stay
3-4 days
Recovery
1-2 weeks
Estimated Price
Approx. $3,800
View Detailed Introduction — Procedure, Price Comparison & More
Price Comparison: China vs. USA
🇨🇳 China
$3,000
🇺🇸 USA
$13,750+
Save up to $10,750 per treatment
Procedure Steps
1
Pre-op: contrast CT/MRI + liver function assessment
2
Local anesthesia + conscious sedation
3
Femoral artery puncture + catheter advancement to hepatic artery
4
Selective catheterization of tumor-feeding artery under fluoroscopy
5
Injection of doxorubicin-loaded drug-eluting beads (DEB-TACE)
6
Embolization with gelfoam/PVA particles
7
Post-embolization syndrome management (pain, fever, nausea)
8
CT assessment at 4-6 weeks (mRECIST criteria)

What is TACE?

Transarterial chemoembolization delivers high-dose chemotherapy directly into the tumor blood supply while blocking its arterial feeding vessels, creating a dual kill mechanism — drug cytotoxicity plus ischemia.

Why China?

  • Highest global experience: Chinese interventional radiologists perform TACE on 50%+ of world HCC cases
  • DEB-TACE standard: Drug-eluting bead technology widely available
  • Cost: $3,000-$5,500 vs. $15,000-$30,000 in the US per session

Who is a candidate?

  • Intermediate-stage HCC (BCLC-B)
  • Unresectable but liver-confined tumor
  • Bridge to transplant
  • Child-Pugh A-B7

Outcomes

Objective response rate: 50-60%. Median survival with repeated TACE: 20-30 months for BCLC-B patients.

Prices are indicative ranges in USD based on partner hospital published rates. Final quote depends on your medical records and selected hospital — request a free personalized estimate.

Why China for Liver Cancer (HCC)

World-leading HCC surgery volume; living-donor liver transplant survival rates match Western centers. ALPPS staged hepatectomy pioneered here.

About Liver Cancer (HCC)

Common Symptoms
  • Right upper abdominal pain
  • Abdominal mass
  • Jaundice
  • Ascites
  • Weight loss
  • Loss of appetite
Common Causes
  • Chronic HBV/HCV
  • Cirrhosis
  • Aflatoxin exposure
  • Alcoholic liver disease
  • NAFLD
Diagnostic Methods
  • AFP serum marker
  • Contrast-enhanced MRI/CT
  • Liver biopsy
  • Indocyanine green retention test